requency of respiratory pathogens other than SARS-CoV-2 detected COVID-1

Autor(es)

Boschiero, Matheus Negri ^{[1, 2]} ; Duarte, Aires ^[3] ; Capasso Palamim, Camila Vantini ^{[1, 2]} ; Alvarez, Alfonso Eduardo ^[4] ; Mauch, Renan Marrichi ^[5] ; Lima Marson, Fernando Augusto ^{[1, 2]}

Afiliação do(s) autor(es)

^[1] Univ Sao Francisco, Lab Cell & Mol Tumor Biol & Bioact Cpds, Braganca Paulista, SP - Brazil

^[2] Univ Sao Francisco, Lab Human & Med Genet, Braganca Paulista, SP - Brazil

^[3] Univ Lisbon, Fac Sci, BioISI Biosyst & Integrat Sci Inst, Lisbon - Portugal

^[4] Pulmonol & Allergy Pediat Ctr, Campinas, SP - Brazil

^[5] Univ Estadual Campinas, Sch Med Sci, Ctr Invest Pediat, Campinas, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE; v. 102, n. 2 FEB 2022.
• Citações Web of Science: 0

Resumo

The frequencies of 19 respiratory pathogens other than SARS-CoV-2 were assessed in 6,235 Brazilian individ-uals tested for COVID-19. Overall, only 83 individuals who tested positive for SARS-CoV-2 had codetection of other pathogens. Individuals infected with Rhinovirus/Enterovirus, Human Coronavirus (HCoV)-HKU1, HCoV-NL63, HPIV-4, Influenza A (-H1N1 and other subtypes), Influenza B, Human Respiratory Syncytial Virus and Human Metapneumovirus were less likely to test positive for SARS-CoV-2. Infection with Streptococcys pyogenes, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Bordetella pertussis were more frequent in individuals who tested negative for SARS-CoV-2, but without significancy. We found 150 individuals infected with >= 2 pathogens other than SARS-CoV-2, only 3 out of whom tested positive for COVID-19. The codetection frequency was low in individuals diagnosed with COVID-19. Other viral infections may provide a cross-reactive, protective immune response against SARS-CoV-2. Screening for bacterial respiratory infec-tions upon COVID-19 testing is important to drive suitable therapeutic approaches and avoid unnecessary antibiotic prescription. (c) 2021 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 21/05810-7 - Síndrome de Down na COVID-19: um estudo observacional do primeiro ano da pandemia no Brasil
• Beneficiário: Matheus Negri Boschiero
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica